Home › Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences
 

Keywords :   


Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences

2015-09-02 07:53:29| drugdiscoveryonline News Articles

Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, recently announced the acquisition of Cardiogen Sciences, Inc., a biotechnology company focused on the discovery and development of adeno-associated virus(AAV) gene therapy products for rare, inherited arrhythmogenic diseases

Tags: company sciences therapy gene

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.12Labelexpo South China 2024 features latest industry trends
03.12PPG Earns Two Awards During CARES 2024 Automotive Forums in U.S., Europe
03.12Filtrex 2025 to be Held in March
03.12Nu-Maber Italy adds dual ThermoFlexX Catena-E 80 units
03.12TEKLYNX assists with label compliance
03.12Megnajet supporting Arrow Systems\' growing digital portfolio
03.12WEG Achieves Gold Certification in EcoVadis for Second Consecutive Year
03.12Bank boss takes pay cut after employee 'tried to kill clients'
More »